These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30775627)

  • 1. Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients.
    Kovesdy CP; Rowan CG; Conrad A; Spiegel DM; Fogli J; Oestreicher N; Connaire JJ; Winkelmayer WC
    Kidney Int Rep; 2019 Feb; 4(2):301-309. PubMed ID: 30775627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization.
    Desai NR; Rowan CG; Alvarez PJ; Fogli J; Toto RD
    PLoS One; 2020; 15(1):e0226844. PubMed ID: 31910208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare utilization and expenditures associated with hyperkalemia management: a retrospective study of Medicare Advantage patients.
    Desai NR; Alvarez PJ; Golestaneh L; Woods SD; Coca SG; Rowan CG
    J Med Econ; 2021; 24(1):1025-1036. PubMed ID: 34357841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing patiromer utilization and associated serum potassium changes in US veterans with prior sodium polystyrene sulfonate exposure.
    Patel S; Pinnell D; Qualls J; Rathod A; Chen W; Boutin S; Woods SD; Kovesdy CP; Tangri N; Sauer BC
    Medicine (Baltimore); 2023 Mar; 102(9):e33134. PubMed ID: 36862858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world management of hyperkalemia with patiromer among United States Veterans.
    Kovesdy CP; Gosmanova EO; Woods SD; Fogli JJ; Rowan CG; Hansen JL; Sauer BC
    Postgrad Med; 2020 Mar; 132(2):176-183. PubMed ID: 31971043
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
    JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis.
    Bushinsky DA; Rossignol P; Spiegel DM; Benton WW; Yuan J; Block GA; Wilcox CS; Agarwal R
    Am J Nephrol; 2016; 44(5):404-410. PubMed ID: 27784004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Pharmacodynamic Effects of the Potassium Binder RDX7675 in Mice.
    Davidson JP; King AJ; Kumaraswamy P; Caldwell JS; Korner P; Blanks RC; Jacobs JW
    J Cardiovasc Pharmacol Ther; 2018 May; 23(3):244-253. PubMed ID: 29130735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease.
    Pinnell D; Patel S; Qualls J; Chen W; Rathod A; Woods SD; Boutin S; Kovesdy CP; Tangri N; Sauer BC
    Medicine (Baltimore); 2022 Dec; 101(50):e32367. PubMed ID: 36550897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
    Kloner RA; Gross C; Yuan J; Conrad A; Pergola PE
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):524-531. PubMed ID: 30103622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Patiromer to Sodium Polystyrene Sulfonate in Acute Hyperkalemia.
    Nguyen PT; Kataria VK; Sam TR; Hooper K; Mehta AN
    Hosp Pharm; 2022 Jun; 57(3):359-364. PubMed ID: 35615481
    [No Abstract]   [Full Text] [Related]  

  • 12. The potassium regulator patiromer affects serum and stool electrolytes in patients receiving hemodialysis.
    Amdur RL; Paul R; Barrows ED; Kincaid D; Muralidharan J; Nobakht E; Centron-Vinales P; Siddiqi M; Patel SS; Raj DS
    Kidney Int; 2020 Nov; 98(5):1331-1340. PubMed ID: 32750456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patiromer for Treatment of Hyperkalemia in the Emergency Department: A Pilot Study.
    Rafique Z; Liu M; Staggers KA; Minard CG; Peacock WF
    Acad Emerg Med; 2020 Jan; 27(1):54-60. PubMed ID: 31599043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patiromer Lowers Serum Potassium When Taken without Food: Comparison to Dosing with Food from an Open-Label, Randomized, Parallel Group Hyperkalemia Study.
    Pergola PE; Spiegel DM; Warren S; Yuan J; Weir MR
    Am J Nephrol; 2017; 46(4):323-332. PubMed ID: 29017162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Patiromer Use and Outcomes Among US Veterans With Hyperkalemia and CKD: A Propensity-Matched Cohort Study.
    Obi Y; Thomas F; Dashputre AA; Goedecke P; Kovesdy CP
    Kidney Med; 2024 Jan; 6(1):100757. PubMed ID: 38192434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patiromer utilization in patients with advanced chronic kidney disease under nephrology care in Germany.
    Pecoits-Filho R; McCullough K; Muenz D; Quinn CM; Budden J; Golden J; de Arellano AR; Tillmann FP; Duttlinger J; Calice-Silva V; Massy ZA; Bieber B; Robinson BM; Fliser D; Reichel H;
    Clin Kidney J; 2023 Jan; 16(1):176-183. PubMed ID: 36726438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patiromer in a Patient with Severe Hyperkalemia on Incremental Hemodialysis with 1 Session per Week: A Case Report and Literature Review.
    De La Flor JC; Deira J; Marschall A; Valga F; Linares T; Monzon T; Albarracín C; Ruiz E
    Case Rep Nephrol Dial; 2021; 11(2):158-166. PubMed ID: 34327218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patiromer: a clinical review.
    Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
    Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patiromer Treatment in Patients With CKD, Hyperkalemia, and Hyperphosphatemia: A Post Hoc Analysis of 3 Clinical Trials.
    Bushinsky DA; Budden JJ; Kalra PA; Yuan J; Quinn CM; Epstein M
    Am J Kidney Dis; 2023 Jul; 82(1):97-104. PubMed ID: 36965827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of patiromer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials.
    Piña IL; Yuan J; Ackourey G; Ventura H
    Prog Cardiovasc Dis; 2020; 63(5):656-661. PubMed ID: 33007353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.